Literature DB >> 4990379

Changes in gut flora after cephalexin treatment.

H Gaya, P I Adnitt, P Turner.   

Abstract

Eighteen patients with urinary tract infection were treated with cephalexin orally. Absorption was variable, between 29 and 89% of the total daily dose being excreted in the urine in 24 hours. A significant number of patients became faecal carriers of Pseudomonas aeruginosa compared with a control group who received no antibiotics. Four of the cephalexin-treated patients acquired a strain of Ps. aeruginosa known to be present in food from the hospital diet kitchen and one developed a urinary tract infection with this strain.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4990379      PMCID: PMC1701693          DOI: 10.1136/bmj.3.5723.624

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  Food and medicaments as possible sources of hospital strains of Pseudomonas aeruginosa.

Authors:  R A Shooter; H Gaya; E M Cooke; P Kumar; N Patel; M T Parker; B T Thom; D R France
Journal:  Lancet       Date:  1969-06-21       Impact factor: 79.321

2.  Cephalexin: microbiological effects and pharmacologic parameters in man.

Authors:  B R Meyers; K Kaplan; L Weinstein
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

3.  Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic.

Authors:  M E Levison; W D Johnson; T S Thornhill; D Kaye
Journal:  JAMA       Date:  1969-09-01       Impact factor: 56.272

4.  Laboratory and clinical experience with cephalexin.

Authors:  A C Kind; D G Kestle; H C Standiford; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

5.  Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic.

Authors:  P E Gower; C H Dash
Journal:  Br J Pharmacol       Date:  1969-11       Impact factor: 8.739

6.  Faecal carriage of Pseudomonas aeruginosa in hospital patients. Possible spread from patient to patient.

Authors:  R A Shooter; K A Walker; V R Williams; G M Horgan; M T Parker; E H Asheshov; J F Bullimore
Journal:  Lancet       Date:  1966-12-17       Impact factor: 79.321

  6 in total
  8 in total

1.  Effect of amoxicillin-clavulanate and cephradine on the fecal flora of healthy volunteers not exposed to a hospital environment.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Colonization resistance of the digestive tract of mice during systemic antibiotic treatment.

Authors:  D van der Waaij; J M Berghuis; J E Lekkerkerk
Journal:  J Hyg (Lond)       Date:  1972-12

Review 3.  Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties.

Authors:  T M Speight; R N Brogden; G S Avery
Journal:  Drugs       Date:  1972       Impact factor: 9.546

4.  Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.

Authors:  B Kemmerich; H Warns; H Lode; K Borner; P Koeppe; H Knothe
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

Review 5.  Antimicrobial prophylaxis in the neutropenic host: lessons of the past and perspectives for the future.

Authors:  L S Young
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

6.  Pseudomonas aeruginosa and Klebsiella pneumoniae on the perinea of males with spinal cord injuries.

Authors:  D S Gilmore; D G Schick; J Z Montgomerie
Journal:  J Clin Microbiol       Date:  1982-11       Impact factor: 5.948

7.  Effect of broad-spectrum parenteral antibiotics on "colonization resistance" of intestinal microflora of humans.

Authors:  M Barza; M Giuliano; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 8.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.